Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect MRD Test in Early Triple-Negative Breast Cancer at SABCS
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect molecular residual disease (MRD...